PharmaFocus Today – Page 4 – media

Surging Flu Data Drives Spike in Drug Demand, With Multiple Companies Including Nuotai Bio and Kangyuan Pharma Accelerating Market Entry

Influenza activity in China has recently entered a phase of rapid growth. The latest data from the Chinese National Influenza Center indicates that during November 10-16, 2025, the proportion of influenza-like illness cases reported by sentinel hospitals in southern provinces reached 6.7% of all outpatient and emergency visits. This represents an increase from the 5.5% recorded the previous week and also surpasses levels observed during the corresponding periods from 2022 to 2024. More recent reports show that the ILI proportion in northern sentinel hospitals has reached as high as 12%, two to three times higher than levels seen during the same periods from 2020 to 2023. Since November, the National Disease Control and Prevention Administration has issued three consecutive “Influenza Orange Alerts,” predicting the peak of this wave will occur between mid-to-late December this year and early January next year. The high incidence relates to this year’s circulating strains. Laboratory ...
- Source: drugdu
- 54
- December 1, 2025
Novartis’ innovative gene therapy receives FDA approval

On November 25, Novartis announced that its gene therapy Itvisma received FDA approval for the treatment of patients aged two years and older diagnosed with spinal muscular atrophy (SMA) and with a surviving motor neuron 1 (SMN1) gene mutation. Notably, this new therapy uses the same active ingredient as Novartis’ earlier Zolgensma therapy, which is primarily designed for SMA patients under two years of age. However, the availability of Itvisma expands the age range of eligible patients and provides them with new treatment options. The wholesale price of Itvisma is $2.59 million, while Zolgensma is $2.1 million. For SMA patients and their families, the successful approval of Itvisma is a major boon. As the only gene replacement therapy currently available for patients aged two years and older, it marks a new milestone in the treatment of this disease. SMA is a rare, inherited neuromuscular disease primarily caused by mutations or ...
- Source: drugdu
- 42
- December 1, 2025
Baili Tianheng receives $250 million in milestone payments

Baili Tianheng announced that SystImmune, Inc. (hereinafter referred to as “SystImmune”) recently received a milestone payment of US$250 million from Bristol-Myers Squibb (hereinafter referred to as “BMS”). The actual amount received will be subject to deduction of bank fees. Baili Tianheng is a comprehensive biopharmaceutical company that focuses on the forefront of global biopharmaceutical fields, is committed to solving unmet clinical needs, has world-leading innovative R&D capabilities, global clinical development and large-scale production and supply capabilities in the field of tumor macromolecular therapy (ADC/GNC/ARC), and will achieve global commercialization capabilities by 2029. Iza-bren (BL-B01D1) is a world-first, novel, and only EGFR×HER3 bispecific antibody ADC independently developed by SystImmune, possessing significant global clinical value and market potential. On December 11, 2023, SystImmune and BMS entered into an exclusive licensing and collaboration agreement (hereinafter referred to as the “Collaboration Agreement”) for the iza-bren (BL-B01D1, EGFR×HER3 bispecific antibody ADC) project. Under the collaboration ...
- Source: drugdu
- 47
- December 1, 2025
Hematological and biochemical indicators show growing value in breast cancer management

Breast cancer remains a predominant global health challenge for women, with late-stage diagnosis being a key contributor to its high mortality. This is particularly pronounced in low-resource settings where access to advanced, costly diagnostic tools is limited. There is a pressing need for affordable, non-invasive, and accessible diagnostic strategies. This review underscores the significant potential of hematological and biochemical serum markers as pivotal tools to bridge this diagnostic gap, offering insights into diagnosis, prognosis, and therapeutic monitoring for breast cancer. Hematological markers associated with breast cancer Hematological markers, derived from routine and inexpensive tests like the complete blood count (CBC), provide a window into the body’s physiological and pathological state, including systemic inflammation and immune response, which are hallmarks of cancer. Formed elements: Studies consistently show significant alterations in the cellular components of blood in breast cancer patients. These include decreases in hemoglobin (Hb) and red blood cell (RBC) counts ...
- Source: drugdu
- 60
- November 28, 2025
Aidoc Submits Breakthrough-Designated Multi-Triage Device for FDA Approval

Aidoc announced its completion of a pivotal study for its multi-triage device, powered by the CARE Foundation Model, designed to detect and prioritize double-digit abdominal conditions within a single solution.1 Following completion of this study, Aidoc submitted its CARE-powered breakthrough-designated device for FDA approval after the device displayed high levels of accuracy in a wide range of abdominal findings.1 “Broad foundation models are the path to expanding clinical AI across care delivery, but only if we raise the safety and quality bar beyond anything the field has seen,” said Elad Walach, CEO and co-founder of Aidoc. “Accuracy that works for one finding won’t hold for many. CARE delivers precision that limits false positives and elevates only what matters, avoiding the noise that has hindered physician adoption. Built for broad, real-world practice, this submission positions Aidoc for a historic first in presumably the most comprehensive CAD.” What is Aidoc’s CARE-powered multi-triage ...
- Source: drugdu
- 62
- November 28, 2025
Johnson & Johnson’s $3.05 billion acquisition of Halda

On November 17, Reuters reported that Johnson & Johnson announced it will acquire privately held oncology therapy research company Halda Therapeutics for $3.05 billion in cash . This acquisition aims to further expand Johnson & Johnson’s business footprint in the treatment of solid tumors and prostate cancer. Halda Therapeutics ‘ core drug candidate, HLD-0915, is currently in early to mid-stage development and is primarily intended for the treatment of prostate cancer. In addition to its core pipeline, the company has several early-stage experimental therapies for breast cancer, lung cancer, and other types of cancer, creating a highly complementary pipeline with Johnson & Johnson’s oncology business. It is worth noting that this is Johnson & Johnson ‘s second major acquisition this year. In January of this year, Johnson & Johnson acquired Intra-Cellular Therapies , a neuropharmaceutical research and development company, for $14.6 billion , continuing to deepen its presence in key ...
- Source: drugdu
- 58
- November 28, 2025
The clinical trials of the new drug for Alzheimer’s disease are progressing smoothly

China Securities News (Reporter Deng Zhen) On November 28th, the Shanghai Securities News learned from Wanbangde that the company has been deeply engaged in the research and development of new drugs for Alzheimer’s disease (AD) for many years, always committed to developing new therapeutic drugs for global AD patients. Currently, the II/III phase key registration clinical trial of the company’s Selonyma Hydrochloride Controlled-release Tablets (FN12) is progressing smoothly. This clinical study is the largest Alzheimer’s disease registration study known in China. The company actively collaborates closely with CRO companies (contract research organizations for pharmaceutical development) to strive to obtain more effective data as soon as possible to verify the efficacy and safety of the drug. Existing data shows that Selonyma Hydrochloride Controlled-release Tablets have good safety. Selonyma, at an appropriate dose, can significantly improve the cognitive function of patients. At the same time, preclinical research shows that Selonyma not only ...
- Source: drugdu
- 56
- November 28, 2025
Medicare is on the move! The US government successfully negotiated lower prices for 15 drugs. The price of semaglutide has dropped by 70%

The US Medicare regulatory agency announced that it has renegotiated the prices of 15 expensive drugs and obtained significant discounts, including the popular weight-loss drug semaglutide; ② The US federal government will purchase semaglutide at a monthly price of $274, while the drug’s list price is $959 per month. On Tuesday local time (November 25th), the US Medicare regulatory agency announced that it has renegotiated the prices of 15 expensive drugs and obtained significant discounts, including the popular weight-loss drug semaglutide, which is produced by the Danish pharmaceutical company Novo Nordisk. It is reported that the discount rates for these 15 drugs range from 38% to 85%, and the new prices will come into effect in 2027. The US federal government will purchase semaglutide at a price of $274 per month (the commercial name for weight loss is Wegovy, and for diabetes it is Ozempic), while the original price of ...
- Source: drugdu
- 58
- November 28, 2025
Data from multiple drugs will be presented at international medical conferences

Zhongzheng Intelligent Finance and HUTCHMED (00013) announced on November 27th in the morning that the latest and updated data of several of the company’s independently developed compounds will be presented at the ESMO Asia Annual Meeting to be held in Singapore from December 5th to 7th, 2025, and at the American Society of Hematology (ASH) Annual Meeting to be held in Orlando, USA from December 6th to 9th. Specifically, the first human clinical trial results of the anti-CD47 monoclonal antibody HMPL-A83 for the treatment of advanced solid tumors, as well as the results of the II phase part of the FRUSICA-2 registration study of the combination of fuyiquitini and xindili monoclonal antibody for second-line treatment of locally advanced or metastatic renal cell carcinoma, will be announced at the ESMO Asia Annual Meeting; the results of the II phase part of the II/III phase study of sorvatinib combined with carlimilizumab and ...
- Source: drugdu
- 54
- November 28, 2025
Relevant flu drugs have not yet been organized for production and sales

On November 26th, Beijing University Pharmaceutical (000788.SZ) issued an announcement regarding abnormal stock trading. The company noticed that there might be a high incidence of influenza in some regions recently， which has drawn attention from the capital market. After self-examination， the company’s related influenza drugs have not yet been organized for production and sales. It is expected that for a considerable period of time in the future, this will not have any impact on the company’s operating performance. https://finance.eastmoney.com/a/202511263575631671.html
- Source: drugdu
- 49
- November 28, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.